title: Curing metastatic cancer: lessons from testicular germ-cell tumours.
abstract: Most metastatic cancers are fatal. More than 80% of patients with metastatic testicular germ-cell tumours (TGCTs), however, can be cured using cisplatin-based combination chemotherapy. Why are TGCTs more sensitive to chemotherapeutics than most other tumour types? Answers to this question could lead to new treatments for metastatic cancers.
authors.affiliation: The Prostate Cancer Research Centre, Institute of Urology, University College London, 3rd Floor, 67 Riding House Street, London W1W 7EJ, UK. j.masters@ucl.ac.uk
authors.forename: John R W
authors.initials: JR
authors.lastname: Masters
authors.forename: Beate
authors.initials: B
authors.lastname: Köberle
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis / Q000503:physiopathology* / Q000628:therapy*; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy*; D013736:Testicular Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin